Abstract: The present invention relates to the preparation of pyridinone carboxylic acid aldehydes such as 5-methoxy-6-(methoxycarbonyl)-4-oxo-1-(2-oxoethyl)-1,4-dihydropyridine-3-carboxylic acid.
Type:
Grant
Filed:
March 22, 2011
Date of Patent:
November 18, 2014
Assignee:
VIIV Healthcare Company
Inventors:
Steven N. Goodman, Matthew David Kowalski, Douglas Matthew Mans, Huan Wang
Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Type:
Application
Filed:
May 21, 2014
Publication date:
September 11, 2014
Applicants:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian Alvin JOHNS, Jason Gordon WEATHERHEAD, Toshikazu HAKOGI, Yasunori AOYAMA
Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Type:
Application
Filed:
February 21, 2014
Publication date:
September 11, 2014
Applicants:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian Alvin JOHNS, Eric Eugene BOROS, Takashi KAWASUJI, Cecilia S. KOBLE, Noriyuki KUROSE, Hitoshi MURAI, Ronald George SHERRILL, Jason Gordon WEATHERHEAD
Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Type:
Application
Filed:
May 20, 2014
Publication date:
September 11, 2014
Applicants:
Shionogi & Co., Ltd., VïïV Healthcare Company
Inventors:
Brian Alvin JOHNS, Jason Gordon WEATHERHEAD, Toshikazu HAKOGI, Yasunori AOYAMA
Abstract: A synthesis approach providing an early ring attachment via a bromination to compound 1-1 yielding compound II-I1, whereby a final product such as AA can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
Type:
Application
Filed:
May 8, 2014
Publication date:
August 28, 2014
Applicants:
Shionogi & Co., Ltd., ViiV Healthcare Company
Abstract: The present invention is to provide a novel compound (I) shown below, having the anti-virus activity; particularly the HIV integrase inhibitory activity, and a drug containing the same, particularly an anti-HIV drug, as well as a process and an intermediate thereof. (wherein Z1 is NR4; R1 is hydrogen or lower alkyl; X is a single bond, a hetero atom group selected from O, S, SO, SO2 and NH, or lower alkylene or lower alkenylene in which the hetero atom group may intervene; R2 is optionally substituted aryl; R3 is hydrogen, a halogen, hydroxy, optionally substituted lower alkyl etc; and R4 and Z2 part taken together forms a ring, to form a polycyclic compound, including e.g., a tricyclic or tetracyclic compound.
Abstract: The present invention is directed to a class of substituted 10-hydroxy-9,11-dioxo-2,3,4a,5,9,11,13,13a-octahydro-1H-pyrido[1,2-a]pyrrolo[1?,2?:3,4]imidazo[1,2-d]pyrazine-8-carboxamides useful as anti-HIV agents. The compounds have the formula (I-1-1): wherein ring A is an optionally substituted hexahydro-1H-pyrrolo[1,2-c]-imidazole; R14 and RX are independently hydrogen or optionally substituted lower alkyl; R3 is selected from various groups; R1 is hydrogen or lower alkyl; R is halogen; m is 0, 1, 2 or 3; or a pharmaceutically acceptable salt thereof.
Type:
Grant
Filed:
February 8, 2013
Date of Patent:
July 15, 2014
Assignees:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian A. Johns, Takashi Kawasuji, Teruhiko Taishi, Yoshiyuki Taoda
Abstract: The compounds are intermediates in the preparation of therapeutic agents useful in the treatment of viral infections, particularly HIV infection. The compounds are 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylic acid of the formula P-6 and/or methyl 1-(2,3-dihydroxypropyl)-4-oxo-3-[(phenylmethyl)oxy]-1,4-dihydro-2-pyridinecarboxylate of the formula P-7.
Type:
Grant
Filed:
October 2, 2013
Date of Patent:
July 1, 2014
Assignees:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian A. Johns, Jason G. Weatherhead, Toshikazu Hakogi, Yasunori Aoyama
Abstract: A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
Type:
Grant
Filed:
December 4, 2013
Date of Patent:
June 17, 2014
Assignees:
Shionogi & Co., Ltd., ViiV Healthcare Company
Abstract: The present invention features compounds that are HIV integrase inhibitors and therefore are useful in the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Type:
Grant
Filed:
February 10, 2005
Date of Patent:
April 8, 2014
Assignees:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian Alvin Johns, Eric Eugene Boros, Takshi Kawasuji, Cecilia S. Koble, Noriyuki Kurose, Hitoshi Murai, Ronald George Sherrill, Jason Gordon Weatherhead
Abstract: The present invention features compounds of formula (I) for the treatment or prevention of HIV infection and for the treatment of AIDS and ARC.
Type:
Grant
Filed:
February 19, 2013
Date of Patent:
April 8, 2014
Assignees:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian A. Johns, Jason G. Weatherhead, Yasunori Aoyama, Hiroshi Yoshida, Yoshiyuki Taoda
Abstract: A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.
Type:
Grant
Filed:
September 5, 2013
Date of Patent:
March 11, 2014
Assignees:
Shiongi & Co., Ltd., VIIV Healthcare Company
Inventors:
Brian Johns, Maosheng Duan, Toshikazu Hakogi
Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Type:
Application
Filed:
October 2, 2013
Publication date:
February 6, 2014
Applicants:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian Alvin JOHNS, Jason Gordon WEATHERHEAD, Toshikazu HAKOGI, Yasunori AOYAMA
Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC.
Type:
Application
Filed:
October 2, 2013
Publication date:
January 30, 2014
Applicants:
Shionogi & Co., Ltd., ViiV Healthcare Company
Inventors:
Brian Alvin JOHNS, Jason Gordon WEATHERHEAD, Toshikazu HAKOGI, Yasunori AOYAMA
Abstract: A synthesis approach providing an early ring attachment via a bromination to compound I-I yielding compound II-II: whereby a final product such as AA: can be synthesized. In particular, the 2,4-difluorophenyl-containing sidechain is attached before creation of the additional ring Q.
Type:
Grant
Filed:
December 8, 2009
Date of Patent:
January 7, 2014
Assignees:
Shionogi & Co., Ltd., ViiV Healthcare Company
Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.
Abstract: The present invention features compounds that are prodrugs of HIV integrase inhibitors and therefore are useful in the delivery of compounds for the inhibition of HIV replication, the prevention and/or treatment of infection by HIV, and in the treatment of AIDS and/or ARC. For example, the present invention includes methyl 3-(benzyloxy)-1-(2,2-dihydroxyethyl)-4-oxo-1,4-dihydropyridine-2 -carboxylate of the formula P-8: and processes for the preparation thereof.
Type:
Grant
Filed:
July 23, 2009
Date of Patent:
November 12, 2013
Assignees:
Shionogi & Co., Ltd., VIIV Healthcare Company
Inventors:
Brian Alvin Johns, Jason Gordon Weatherhead, Toshikazu Hakogi, Yasunori Aoyama
Abstract: Processes are provided which create an aldehyde methylene, or hydrated or hemiacetal methylene attached to a heteroatom of a 6 membered ring without going through an olefinic group and without the necessity of using an osmium reagent. In particular, a compound of formula (I) can be produced from (II) and avoid the use of an allyl amine: (formulae I and II) where R, P1 P3, R3 and Rx are as described herein.
Type:
Grant
Filed:
December 9, 2009
Date of Patent:
October 8, 2013
Assignees:
Shionogi & Co., Ltd., VIIV Healthcare Company
Inventors:
Brian Alvin Johns, Maosheng Duan, Toshikazu Hakogi
Abstract: The present Invention relates to pharmaceutical compositions of (3S,11aR)-N-[(2,4-difluorophenyl)methyl]-2,3,5,7,11,11a-hexahydro-6-hydroxy-3-methyl-5,7-dioxo-oxazolo[3,2-a]pyrido[1,2-d]pyrazine-8-carboxamide, useful in the treatment or prevention of Human Immunodeficiency Virus (HIV) infections.